ProFibrix BV, a Leiden-based biotech company focused on products to stop bleeding and initiate tissue repair, has closed a Series A financing round raising $11m. The round was led by Index Ventures and backed by some of the current share holders of ProFibrix. It was also announced that Dr. Bram Bout, who previously held the position of VP protein production at Crucell and has approximately 15 years experience in the biopharmaceutical industry, has joined ProFibrix as of 1 April 2007 as chief technology officer.
Noerr’s Holger Ebersberger and Latham & Watkins’ Hanno Witt to join the firm’s Munich office
London-headquartered GP invested in AI provider MIcompany in first deal for new strategy this week
VC firm aims to raise USD 75m-150m from private and public investors including blue-chip institutional LPs in Europe, MENA and US
More than twice the size of its 2019 predecessor, the vehicle will allow for larger equity tickets, more investments and bolt-ons